There is a molecule moving through late-stage trials that, in those trials, posted weight-loss numbers people used to associate only with surgery. It is not approved. It is not a shortcut. And the most interesting thing about it is not the number on the scale. It is called retatrutide.
If you follow the GLP-1 world at all, you are about to hear this name constantly. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) defined the last few years. Retatrutide is the molecule people expect to define the next one. This is a plain-English explainer of what it is, what the trial data actually shows, and what a data-minded person would want to track, framed entirely as education rather than advice.
Read this first. Retatrutide is an investigational drug. As of 2026 it is in Phase 3 trials and is not approved by the FDA for any use, so it has no established real-world safety or efficacy profile. Nothing here is medical advice, dosing guidance, or a recommendation to obtain or use it. The goal is to help you understand the science and what responsible tracking looks like, in partnership with your physician.
What Retatrutide Actually Is
The incretin drugs work by mimicking gut hormones that control appetite and blood sugar. What separates them is how many receptors they hit. Think of it as a ladder, with each rung adding a mechanism:
| Class | Receptors | Examples |
|---|---|---|
| Single agonist | GLP-1 | semaglutide, liraglutide |
| Dual agonist | GLP-1 + GIP | tirzepatide |
| Triple agonist | GLP-1 + GIP + glucagon | retatrutide |
Retatrutide adds a third lever the others do not pull: glucagon. Most people associate glucagon with raising blood sugar, but at the receptor level it also increases energy expenditure and pushes the liver to burn fat. So instead of working on appetite alone, a triple agonist is designed to turn down intake and turn up output at the same time. That combination is thought to be why the trial results look the way they do.
The Data That Changed the Conversation
The headline trial is TRIUMPH-1, a Phase 3 study in 2,339 adults with obesity but without diabetes. TRIUMPH-1 reported that, at the highest dose studied, participants lost an average of 28.3% of their body weight over 80 weeks, with 45.3% of them losing at least 30%. In a study extension, participants who started with a BMI of 35 or higher reached an average of 30.3% loss at 104 weeks. Coverage of the result noted that this approaches the range historically associated with bariatric surgery, from a once-weekly injection.
Lower doses reported smaller average losses, which is the expected dose-response pattern. Two things are worth keeping in mind: these are trial-reported averages, not real-world outcomes, and a Phase 3 readout is not the same thing as an approved, established therapy. The numbers are striking. They are also provisional.
Why the Scale Is the Least Interesting Part
The reason data people are paying attention is not the weight. It is what retatrutide appeared to do, in the trials, to the markers underneath cardiovascular and metabolic risk. Reported reductions spanned the cardiometabolic panel, alongside a genuinely unusual kidney signal:
- Triglycerides: reported down roughly 40%.
- LDL cholesterol: reported down roughly 20%.
- ApoB: expected to track those LDL and non-HDL reductions, which matters more than LDL alone because ApoB counts the actual particle burden.
- hs-CRP: large reported reductions in inflammation, the marker that tracks aging before you feel it.
- eGFR: a small reported increase in kidney filtration, which is unusual and notable.
This is the basis for the “metabolic fix-it-all” nickname the drug has picked up in coverage. Whether those trial-reported signals translate into long-term outcomes is exactly what later research has to establish. The relevant point for tracking is simpler: changes like these are the kind of progress a scale physically cannot display, which is the argument for watching the panel and not the pounds.
The Risk Nobody Puts on the Box: Muscle
Deeper weight loss raises the stakes on body composition. Across the incretin therapies studied so far, roughly 25 to 39% of the total weight lost has been fat-free mass when no preservation protocol is applied. The more total weight a therapy moves, the more lean mass is potentially in play, so without adequate protein and resistance training a meaningful slice of any large loss can come from muscle rather than fat.
Muscle is the metabolic engine that defends weight loss over the long run, which is why losing it is the mechanism behind so much post-medication rebound. This is the single most important thing to get right, and it is fully within your control. We wrote a dedicated playbook on it: how to keep muscle on a GLP-1.
The Safety Signal Worth Knowing
The most-discussed adverse signal in late-stage retatrutide data is dysesthesia, an abnormal skin sensitivity, which appeared to be dose-dependent in the trials. As with the approved drugs in this class, gastrointestinal effects such as nausea and reduced appetite were commonly reported, especially while the dose was being increased. None of this is a reason for alarm or a reason for confidence. An investigational drug does not yet have a complete, established safety profile; these are signals as reported in ongoing trials, not the full picture. Whether and how to use any medication is a decision for a licensed clinician, not an app and not an article.
What a Data-Minded Person Would Track
If retatrutide is ever approved and prescribed, the people who get the most out of it will not be the ones watching the scale. They will be the ones treating it like a measured intervention, alongside their clinician. For any prescribed incretin therapy, that means tracking:
- Rate of loss, not just total loss — too fast, week over week, is the clearest muscle-risk flag.
- Protein intake against a body-weight floor — the hardest thing to hit when a drug is suppressing your appetite.
- Resistance-training frequency — the behavioral lever that converts loss from muscle-shedding to fat-targeting.
- The cardiometabolic panel over time — ApoB, triglycerides, hs-CRP, fasting glucose. This is your proof beyond the scale.
- Body composition, ideally by DEXA — the only way to know whether you are losing fat or muscle.
- How you feel, logged over time — so that any dose decisions stay with your prescriber and are made on data, never on guesswork.
Mallet is built for the part the prescription does not handle. It sets a medication-aware protein floor, scores how well you are preserving muscle as the weight comes off, and tracks the cardiometabolic markers (ApoB, triglycerides, hs-CRP, glucose) that show whether progress is happening beyond the scale. It is a tracking and education companion, never a source of dosing advice. Get early access →
Selected References
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Investor news release. 2026.
- American Journal of Managed Care. Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial. 2026.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). New England Journal of Medicine. 2023.
This article is for education, not medical advice. Retatrutide is investigational and not FDA-approved. Discuss any medication decision with a licensed clinician.